Over 150 Total Lots Up For Auction at Three Locations - WI 05/27, NV 05/29, CA 06/06

Dr. Carri Glide-Hurst

American Association of Physicists in Medicine elects fellow
September 04, 2018
Rad Oncology Radiation Therapy
Dr. Carri Glide-Hurst
DETROIT – Henry Ford Cancer Institute medical physicist Carri K. Glide-Hurst, Ph.D., DABR, has been elected to be a Fellow of the American Association of Physicists in Medicine (AAPM), a prestigious international organization of 8,500 medical physicists in 93 countries.

Dr. Glide-Hurst, the director of Translational Research in Radiation Oncology at Henry Ford, was presented with the fellowship award at the Annual Meeting of the American Association of Physicists in Medicine in Nashville, TN.

The category of AAPM Fellow honors members who have distinguished themselves by their contributions in research, education, or leadership in the medical physics community. The AAPM supports the medical physics community with a focus on advancing patient care through education, improving safety and efficacy of radiation oncology and medical imaging procedures through research, and the maintenance of professional standards.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats
Dr. Glide-Hurst is nationally recognized for work with magnetic resonance simulation (MR-SIM) and MR‐guided radiation therapy, including implementation at the Henry Ford Cancer Institute of the world’s first FDA-approved linear accelerator-based MRI-guided radiation therapy system, ViewRay MRIdian Linac.

Additionally, Dr. Glide-Hurst was awarded a prestigious NIH R01 on MR-only treatment planning and is primary investigator or co-primary investigator on 11 other grants. She has published 48 manuscripts, four book chapters, 125 abstracts, and holds one patent.

She serves on nine AAPM committees, most notably the Strategic Planning Committee, Board of Directors, co-chair of TG-284 on MR-SIM, Annual Meeting Scientific Track co-director, and AAPM Summer School faculty. She also serves on ABR Medical Physics Parts 2 and 3 Therapy Exam Committees.

Dr. Glide-Hurst also has a passion for mentoring future physicists. During her career, she has mentored 14 residents and 17 researchers.

Dr. Glide-Hurst received a Ph.D. in medical physics from Wayne State University and completed two years of postdoctoral training at Beaumont Health.

You Must Be Logged In To Post A Comment

 

classifieds

Rad Oncology Homepage

UT Southwestern starts construction on $177 million radiation oncology facility in Texas
The 65,000-square-foot facility will include four linear accelerators
FDA expands clearance for P-Cure proton therapy system to full-body and supine treatments
Gantry-less architecture enables installation in vaults originally designed for linear accelerators
TriHealth partners with RevealDx to advance lung nodule assessment using AI
Adds AI-driven decision support to expanding lung cancer program
RaySearch launches RayStation v2025 with expanded auto-planning
Adds support for treatment planning using the Leo Cancer Care upright patient positioning system
GE HealthCare adds AI-driven tools to radiation oncology portfolio
Plans to integrate software from Spectronic Medical into portfolio
P-Cure opens second Israel facility to scale compact proton therapy production
Will handle manufacturing and assembly of the company’s proprietary accelerator technology
Sun Nuclear acquires AI software firm Oncospace to bolster radiation oncology tools
Integrates predictive analytics and cloud-based planning solutions
Penn Medicine to add $224 million proton center, ramp up FLASH research
Will house two ProteusONE proton therapy systems from IBA in a 43,000-square-foot space
Will you be attending this year's National Proton Conference?
Q&A with Jennifer Maggiore, the National Association for Proton Therapy’s (NAPT) executive director
Varian and Embolx to jointly market embolization microcatheter in US
Expanding interventional oncology portfolio with a focus on liver-directed therapies